Transcatheter Tricuspid Valve Annuloplasty vs Edge-to-Edge Repair: A Propensity-Matched Multicenter Comparative Analysis.
Open Access CRIS of the University of Bern · 2026-07-21
DOI: 10.48620/99743 ↗At a glance
Journal article in Open Access CRIS of the University of Bern, published on 2026-07-21. Written by Jennifer von Stein and 40 co-authors.
Abstract (original language)
Background
Transcatheter tricuspid valve (TV) interventions are an effective treatment option for patients with severe symptomatic tricuspid regurgitation (TR). TV transcatheter edge-to-edge repair (T-TEER) and transcatheter TV annuloplasty (TTVA) represent distinct repair strategies; however, comparative data remain limited.
Objectives
The objective of the study was to compare procedural and clinical outcomes after T-TEER and TTVA in patients with severe secondary TR.
Methods
Consecutive T-TEER or TTVA-treated patients (2017-2024) were included. A 1:1 propensity-score matching was performed. Endpoints included residual TR ≤ 1+/≤2+, a ≥2-grade reduction, procedural complications, symptomatic improvement, reinterventions, and the composite of all-cause mortality or first heart failure hospitalization within 1 year.
Results
Among 1,122 patients (882 T-TEER; 240 TTVA), 111 well-balanced matched pairs were identified. At discharge, T-TEER achieved higher rates of residual TR ≤ 1+ (50.0% vs 34.2%) and ≤2+ (87.7% vs 67.6%; all P < 0.05) compared with TTVA, whereas a ≥2-grade reduction was comparable. Procedural complications were less frequent with T-TEER (any complication: 4.5% vs 27.0% for T-TEER vs TTVA; P < 0.001). Symptomatic improvement and reintervention rates within 1 year were similar between groups. Freedom from the composite endpoint of all-cause mortality or first heart failure hospitalization at 1-year was 75.0% (95% CI: 66.8-84.1) after T-TEER and 79.8% (95% CI: 72.4-87.9) after TTVA (P = 0.408).
Conclusions
In patients with severe secondary TR and sufficient clinical and anatomical overlap for matched comparison, T-TEER showed a more favorable safety profile and more effective, durable TR reduction, whereas early clinical outcomes at 1 year were comparable after adjustment for baseline differences, highlighting the need for longer-term evaluation.
Subjects
Cite
APA
Stein, J. V., Stein, P. V., Stolz, L., Althoff, Jan, Hasse, C., Rosch, S., Rudolph, F., Kirchner, J., Goebel, B., Koell, B., Rottbauer, W., Rassaf, T., Beucher, H., Kraus, M., Kassar, M., Geisler, T., Rück, A., Ferreira-Martins, J., …, & Wild, M. G. (2026). Transcatheter Tricuspid Valve Annuloplasty vs Edge-to-Edge Repair: A Propensity-Matched Multicenter Comparative Analysis. Open Access CRIS of the University of Bern. https://doi.org/10.48620/99743
Vancouver
Stein JV, Stein PV, Stolz L, Althoff, Jan, Hasse C, et al. Transcatheter Tricuspid Valve Annuloplasty vs Edge-to-Edge Repair: A Propensity-Matched Multicenter Comparative Analysis. Open Access CRIS of the University of Bern. 2026. doi:10.48620/99743
BibTeX
@article{Stein2026,
author = {Stein, Jennifer von and Stein, Philipp von and Stolz, Lukas and Althoff and Jan and Hasse, Caroline and Rosch, Sebastian and Rudolph, Felix and Kirchner, Johannes and Goebel, Bjoern and Koell, Benedikt and Rottbauer, Wolfgang and Rassaf, Tienush and Beucher, Harald and Kraus, Martin and Kassar, Mohammad and Geisler, Tobias and Rück, Andreas and Ferreira-Martins, Joao and Toggweiler, Stefan and Sagmeister, Paula and Westermann, Dirk and Stocker, Thomas J. and Weckbach, Ludwig T. and Näbauer, Michael and Dawkins, Sam and Kister, Tobias and Vorpahl, Marc and Konstandin, Mathias H. and Luedike, Peter and Kessler, Mirjam and Iliadis, Christos and Lauten, Philipp and Besler, Christian and Kalbacher, Daniel and Friedrichs, Kai P. and Gerçek, Muhammed and Granada, Juan F. and Lurz, Philipp C. and Hausleiter, Jörg and Wild, Mirjam Gauri},
title = {Transcatheter Tricuspid Valve Annuloplasty vs Edge-to-Edge Repair: A Propensity-Matched Multicenter Comparative Analysis},
journal = {Open Access CRIS of the University of Bern},
year = {2026},
doi = {10.48620/99743}
}
EUVIMED